Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Long-Term Investments (2018 - 2025)

Historic Long-Term Investments for Abvc Biopharma (ABVC) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Abvc Biopharma's Long-Term Investments rose 1762.24% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 1762.24%. This contributed to the annual value of $2.3 million for FY2024, which is 1064.14% down from last year.
  • Abvc Biopharma's Long-Term Investments amounted to $2.7 million in Q3 2025, which was up 1762.24% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Long-Term Investments peaked at $2.8 million during Q2 2025, and registered a low of $816160.0 during Q3 2022.
  • For the 5-year period, Abvc Biopharma's Long-Term Investments averaged around $1.7 million, with its median value being $1.1 million (2021).
  • As far as peak fluctuations go, Abvc Biopharma's Long-Term Investments tumbled by 5011.61% in 2021, and later surged by 22804.78% in 2023.
  • Quarter analysis of 5 years shows Abvc Biopharma's Long-Term Investments stood at $932755.0 in 2021, then fell by 9.72% to $842070.0 in 2022, then skyrocketed by 200.18% to $2.5 million in 2023, then dropped by 10.64% to $2.3 million in 2024, then increased by 21.54% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.8 million for Q2 2025, and $2.8 million during Q1 2025.